Request Legal Help Now - Free

Advertisement
LAWSUITS NEWS & LEGAL INFORMATION

Coumadin (Warfarin) Legal News Articles & Interviews

View Lawyer Interviews only

Alere Inaccuracies may lead to Legal Action

Alere Inaccuracies may lead to Legal Action September 24, 2016. By Jane Mundy.
Dallas, TX: Now that the blood-testing device called Alere INRatio is known to cause misreadings, attorneys are beginning to focus on blood thinner-related injuries. And there may be legal action against Alere, the manufacturer.
Read [ Alere Inaccuracies may lead to Legal Action ]

Coumadin: “The Most Dangerous Drug in America”

Coumadin: “The Most Dangerous Drug in America” September 20, 2015. By Gordon Gibb.
Asheville, NC It can easily be said that the pressure on Coumadin (warfarin) has been off ever since the two newer blood thinners Pradaxa and Xarelto have been on the market and commanding headlines with their inherent lack of antidotes (although a reversing agent for Pradaxa is currently in the pipeline for FDA approval).
Read [ Coumadin: “The Most Dangerous Drug in America” ]

Is Coumadin on the Way Out?

Is Coumadin on the Way Out? May 10, 2015. By Heidi Turner.
Seattle, WA Because it has been around for so many years, Coumadin was widely regarded as the gold standard for anticoagulant medications. New medications have come along to replace Coumadin, claiming to not carry the same risk of Coumadin side effects - or the same need for blood monitoring. But because Coumadin (known also as warfarin) has an antidote, it has survived competition from the newer drugs.
Read [ Is Coumadin on the Way Out? ]

Drug Tops Warfarin in Important Study

Drug Tops Warfarin in Important Study December 7, 2010. By Charles Benson.
Chicago, IL Johnson & Johnson and Bayer AG's blood-thinning drug Xarelto was better at preventing strokes in patients with erratic heartbeats without increasing the risk of bleeding than warfarin therapy, according to a new study.
Read [ Drug Tops Warfarin in Important Study ]

Race to Replace Warfarin Chases a Potential $20 Billion US Market

Race to Replace Warfarin Chases a Potential $20 Billion US Market October 15, 2010. By Gordon Gibb.
Washington, DC It's been around for 60 years and is one of the most common, go-to blood thinners prescribed to patients as a means to break up—or ward against—blood clots. But Warfarin, known commercially as Coumadin or Jantoven, is a complex drug that's not easy to get right. Until recently, methods used to determine a patient's suitability and tolerance for Warfarin have been described as "archaic."
Read [ Race to Replace Warfarin Chases a Potential $20 Billion US Market ]


Request Legal Help Now! - Free